SLNCF Silence Therapeutics plc

BEARISH Impact: 5/10 EFFECT
Horizon immediate Filed May 28, 2026 Processed 16d 5h ago SEC 9999999995-26-001774
IPO/offering going effective
Latest settled — T+5d ⚠ clustered
SLNCF ▲ 0.00% at T+5d
SHORT call ✗ call lost 0.00% · α vs SPY +0.32% · entry $1.06 → $1.06
Next anchor: T+20d in 13d
Currently $1.06 · +0.00% from $1.06 entry (call sign-flipped)
Entry anchored
May 28, 2026
via day open
T+1d
0.00%
call 0.00% · α +0.24%
$1.06
settled 15d ago
T+5d
0.00%
call 0.00% · α +0.32%
$1.06
settled 9d ago
T+20d
call — · α —
in 13d
T+60d
call — · α —
in 2mo

Price Chart

Loading chart...

Executive Summary

Silence Therapeutics' $300M universal shelf registration (including a $100M ATM facility) became effective on May 27, 2026. The company, with $70.1M in cash and a $15M quarterly net loss, can now sell shares at any time, creating near-term dilution overhang ahead of Phase 2 SANRECO data in August 2026.

Actionable Insight

The shelf activation increases the likelihood of near-term share sales to fund operations. Watch for any ATM takedown announcements, which would signal immediate dilution. The Phase 2 SANRECO readout in August 2026 is the key catalyst; any offering before then may pressure the stock.

Key Facts

  • Effectiveness date: May 27, 2026 for shelf registration on Form S-3 (File No. 333-295992).
  • Shelf includes up to $300M in securities, with an ATM facility for up to $100M in ADSs via Jefferies.
  • Q1 2026 cash and short-term investments: $70.1M; net loss: $15.0M; revenue: $0.4M.
  • Phase 2 SANRECO topline data expected August 2026.

Financial Impact

Potential dilution of up to $300M (or $100M through ATM) against current market cap. Exact impact depends on timing and pricing of any takedowns.

dilutioncash runwayshare count

Risk Factors

  • Dilution from ATM or follow-on offerings under the shelf.
  • Cash burn rate may accelerate, forcing earlier or larger offerings.
  • Negative Phase 2 data could compound dilution impact.

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
EFFECT Filing (Primary)9999999995-26-001774
Document: 9999999995-26-001774-index.html9999999995-26-001774
Document: 9999999995-26-001774.txt9999999995-26-001774
4 reports for SLNCF
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for SLNCF — sortable, filterable
Type Now
May 28, 2026
16d ago
EFFECT
BEARISH ★ 5/10
$1.06 $1.06· 0.00%▲ +0.32%$1.06 (+0.00%)
May 27, 2026
16d ago
424B5
BEARISH ★ 6/10
$1.06 $1.06· 0.00%▲ +0.32%$1.06 (+0.00%)
May 18, 2026
25d ago
S-3
BEARISH ★ 6/10
$1.45 $1.06▲ +27.02%▲ +29.32%$1.06 (+27.02%)
May 7, 2026
5w ago
8-K
NEUTRAL ★ 4/10
$2.63 $1.45▼ −44.77%▼ −46.28%$1.06 (−59.70%)
Showing 4 of 4

US Market Status

Market Closed — Opens Mon (45h 31m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access